target audience: TECH BUYER Publication date: Feb 2023 - Document type: IDC PlanScape - Doc Document number: # US50241323
IDC PlanScape: Measuring and Scaling the ROI on Decentralized Clinical Trials for the Life Science Industry
Content
List of Tables
List of Figures
Get More
When you purchase this document, the purchase price can be applied to the cost of an annual subscription, giving you access to more research for your investment.
Related Links
Abstract
This IDC PlanScape addresses the growing importance of decentralized clinical trials (DCTs), provides insights on the benefits and challenges associated with DCTs, identifies the key stakeholders involved, and provides guidance to the life science industry on how to choose the right partners and which are the critical key performance indicators (KPIs) that should be monitored to optimize the return on investment.
"Decentralized clinical trials are reshaping the life science industry. As organizations are rapidly attempting to transition from a 'pilotitis' mode to an enterprisewide implementation strategy, they need to take cognizance of the importance of defining key performance indicators, which will serve as measures of success through their DCT journey. The life science industry needs to develop a 'DCT Organizational Maturity Score' for DCT implementation, akin to a capability maturity model (CMM), which will help organizations to benchmark their performance, against themselves and against the industry," says Dr. Nimita Limaye, research vice president, Life Sciences R&D Strategy and Technology at IDC Health Insights.